以BAFF/APRIL为靶点药物治疗系统性红斑狼疮临床研究进展  

Research progress of drugs targeting BAFF/APRIL for systemic lupus erythematosus

作　　者：刘丹[1] 王晓霞[2] 王洪[2] 何佳莉 吴佩涵 刘桂海 LIU Dan;WANG Xiao-xia;WANG Hong;HE Jia-li;WU Pei-han;LIU Gui-hai(Graduate Departments of Shanxi Medical University,Taiyuan 030000,China;The Second Hospital ofShanxi Medical University,Taiyuan 030000,China)

机构地区：[1]山西医科大学研究生院,太原030000 [2]山西医科大学第二医院,太原030000

出　　处：《中国新药杂志》2021年第6期535-539,共5页Chinese Journal of New Drugs

摘　　要：系统性红斑狼疮(SLE)是一种以致病性自身抗体和免疫复合物形成并介导器官、组织损伤的自身免疫性疾病,近年来不少国内外学者发现B淋巴细胞在SLE的发病中扮演了重要的角色,本文主要对以BAFF/APRIL为靶点的药物治疗SLE的临床试验进展进行综述。Systemic lupus erythematosus(SLE)is an autoimmune disease caused by the forming of pathogenic autoantibodies and immune complexes which mediate organ and tissue damages.In recent years,many scholars have found that B lymphocytes play an important role in the pathogenesis of SLE.This article mainly reviews the progress of clinical trials of drugs targeting BAFF/APRIL.

关 键 词：系统性红斑狼疮 B淋巴细胞活化因子/增殖诱导配体 临床试验 

分 类 号：R969.4[医药卫生—药理学]